Donor-Derived Cell-Free DNA as a Prognostic Biomarker in Severe Cardiac Allograft Rejection: From Detection to Risk Stratification
Posted inClinical Updates news Pathology & Lab Medicine Transplantation

Donor-Derived Cell-Free DNA as a Prognostic Biomarker in Severe Cardiac Allograft Rejection: From Detection to Risk Stratification

Recent heart-transplant studies show donor-derived cell-free DNA not only detects rejection but also predicts mortality and persistent graft dysfunction, especially when elevated at diagnosis. Evidence supports a shift from binary surveillance toward risk-adapted management.
Circulating MicroRNA Scores May Distinguish Cellular and Antibody-Mediated Heart Transplant Rejection With High Accuracy
Posted inCardiology news Pathology & Lab Medicine/Bệnh học

Circulating MicroRNA Scores May Distinguish Cellular and Antibody-Mediated Heart Transplant Rejection With High Accuracy

A prospective multicenter study found circulating microRNA rejection scores identified ACR and AMR with strong diagnostic performance and prognostic value, supporting their development as noninvasive tools to reduce reliance on surveillance biopsy after heart transplantation.
Misaligned Urgency: Why Status Exceptions May Be Paradoxically Lowering Priority for the Sickest Children in Heart Transplantation
Posted inCardiology news Pediatrics

Misaligned Urgency: Why Status Exceptions May Be Paradoxically Lowering Priority for the Sickest Children in Heart Transplantation

A large-scale analysis of 6,026 pediatric heart transplant candidates reveals that status exceptions often prioritize patients with lower mortality risk than those meeting standard criteria, highlighting a significant misalignment in the U.S. allocation system that the National Heart Review Board has yet to resolve.
Post-Heart Transplantation Survival Comes with a Heavy Cardiovascular-Kidney-Metabolic Burden: New Data on DM2 and CKD Risks
Posted inCardiology Nephrology news Transplantation

Post-Heart Transplantation Survival Comes with a Heavy Cardiovascular-Kidney-Metabolic Burden: New Data on DM2 and CKD Risks

A longitudinal study of 944 heart transplant recipients reveals a staggering incidence of metabolic and renal dysfunction. While diabetes significantly increases mortality risk, the study highlights the potential of SGLT2 inhibitors and GLP1RAs to mitigate these chronic complications in the post-transplant population.